Conclusion With greater accuracy and fewer demands for invasive testing, ffDNA is set to change the way we screen for chromosomal anomalies in pregnancy. However, setting up a new screening program has its challenges and is costly. Discussion as to how the NHS implements ffDNA into the screening service is vital if it is to successfully negotiate changes in service implementation. The importance of counselling and informed consent should not be overlooked when discussing ffDNA with patients, so they can understand the choices they face and the implication of any screening.
References 1.
Soothill P 2. 3. 4. , Lo Y . Non-invasive prenatal testing for chromosomal abnormality using maternal plasma DNA. RCOG Scientific impact paper No.15, 2014.
Russo M, Blakemore K. A historical and practical review of first trimester aneuploidy screening practice points. Seminars in Fetal and Neonatal Medicine 2014;19(3):183-187.
Morris S, Karlsen S, Chung N. Model-based analysis of costs and outcomes of non-invasive prenatal testing for Down’s syndrome using cell free fetal DNA in the UK National Health Service. PLoS One 2014;9(4)e93559.
Committee Opinion No. 545: Noninvasive prenatal testing for fetal aneuploidy 120(6):1532-1534.
5. Wegner R, Stumm M, Hofmann W experience in Germany
6. 7. Gromminger S, Y 8. 9. F . Molecular Cytogenetics 2014;7(suppl 1):14.
Bianchi D, Parker R, Wentworth J et al. DNA sequencing versus standard prenatal aneuploidy screening. The New England Journal of Medicine 2014; 370(9) 799-808.
agmur E, Erkan S et al. Fetal aneuploidy detection by cell-free DNA sequencing for multiple pregnancies and quality issues with vanishing twins. Journal of Clinical Medicine 2014;3:679-692.
ECRI Institute Evidence Report: First trimester combined screening for chromosomal abnormalities 2008; 155:1-90. auzdar A. Non-invasive prenatal testing (NIPT): a better option for patients. Moleuclar Cytogenetics 2014;7 (suppl 1):17.
10. Sayres L, Allyse M, Goodspeed T et al. Demographic and experimental correlates of public attitudes towards cell-free fetal DNA screening. Journal of Genetic Counselling 2014, 23(6): 957-967.
11. Sayres L, Allyse M, Cho M Integrating stakeholder perspectives into the translation of cell-free fetal DNA testing for aneuploidy
. Genome Medicine 2012;4(6)49. 12. T
urner A, Rad S, Afshar Y et al. Declining rate of invasive procedures for prenatal diagnosis in the era of noninvasive prenatal testing. Obstetrics and Gynecology 2014;123(5)196s.
13. Robson S, Martin W , Morris R. The investigation and management of the small for gestational age fetus. Royal college of Obstetricians and Gynaecologists. Greentop Guideline no. 31. 2013.
ABOUT THE AUTHORS Dr Michelle Kemp is an Obstetric and Gynaecology Registrar at the Norfolk and Norwich University Hospital. She has an interest in fetal and maternal medicine, and enjoys teaching medical students.
Mr Richard Smith has been a Consultant Obstetrician and Subspecialist in fetal medicine for eight years. He has trained in East Anglia, London, and Bristol. He has been a member of the National Screening Committee, the regional ultrasound training coordinator for obstetrics and gynaecology trainees, and is the prize coordinator for the British Maternal and Fetal Medicine Society.
-25- . Obstetrics and Gynecology 2012; . Non-invasive prenatal diagnosis using massively parallel sequencing – first
Page 1 |
Page 2 |
Page 3 |
Page 4 |
Page 5 |
Page 6 |
Page 7 |
Page 8 |
Page 9 |
Page 10 |
Page 11 |
Page 12 |
Page 13 |
Page 14 |
Page 15 |
Page 16 |
Page 17 |
Page 18 |
Page 19 |
Page 20 |
Page 21 |
Page 22 |
Page 23 |
Page 24 |
Page 25 |
Page 26 |
Page 27 |
Page 28 |
Page 29 |
Page 30 |
Page 31 |
Page 32 |
Page 33 |
Page 34 |
Page 35 |
Page 36 |
Page 37 |
Page 38 |
Page 39 |
Page 40 |
Page 41 |
Page 42 |
Page 43 |
Page 44 |
Page 45 |
Page 46 |
Page 47 |
Page 48 |
Page 49 |
Page 50 |
Page 51 |
Page 52 |
Page 53 |
Page 54 |
Page 55 |
Page 56 |
Page 57 |
Page 58 |
Page 59 |
Page 60 |
Page 61 |
Page 62 |
Page 63 |
Page 64 |
Page 65 |
Page 66 |
Page 67 |
Page 68